GeneOne Life Science, Inc. (KRX:011000)

South Korea flag South Korea · Delayed Price · Currency is KRW
869.00
+60.00 (7.42%)
At close: May 7, 2026
Market Cap73.35B -52.6%
Revenue (ttm)23.04B -35.5%
Net Income-51.85B
EPS-629.00
Shares Out90.67M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,514,514
Average Volume7,310,677
Open783.00
Previous Close809.00
Day's Range783.00 - 930.00
52-Week Range618.00 - 4,270.00
Beta0.51
RSI45.43
Earnings DateMay 14, 2026

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1976
Employees 41
Stock Exchange Korea Stock Exchange
Ticker Symbol 011000
Full Company Profile

Financial Performance

In 2025, GeneOne Life Science's revenue was 23.04 billion, a decrease of -35.49% compared to the previous year's 35.72 billion. Losses were -51.85 billion, 6.83% more than in 2024.

Financial Statements